Cagrilintide is a long-acting analogue of amylin used in research into appetite regulation and weight management. Preclinical and early clinical studies have shown dose-dependent reductions in body weight and waist circumference, with the peptide reducing fat mass while maintaining lean mass by acting on amylin receptor subtypes 1 and 3. Researchers study cagrilintide in combination with GLP-1 agonists to explore its potential to enhance satiety, reduce energy intake and treat obesity and type 2 diabetes.

For laboratory research use only. Not for human use.